deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02709889

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors

Sponsor: AbbVie

Conditions Glioblastoma High Grade Gastroenteropancreatic Neuroendocrine Carcinoma Large-Cell Neuroendocrine Carcinoma Malignant Melanoma Medullary Thyroid Cancer Neuroendocrine Prostate Cancer Other Neuroendocrine Carcinoma Other Solid Tumors
Interventions Dexamethasone Rovalpituzumab tesirine
Updated 17 times since 2017 Last updated: Sep 21, 2020 Started: Sep 23, 2016 Primary completion: Aug 27, 2019 Completion: Aug 27, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic considerations

Other terminated trials from AbbVie

See all terminations from AbbVie

Other Glioblastoma trials with similar outcome

Browse all Glioblastoma trials

A PHASE1/PHASE2 clinical study on Glioblastoma and High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, this trial is terminated or withdrawn. The trial is conducted by AbbVie and has accumulated 17 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Nov 2020 · 13 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Oct 2019 — Nov 2020 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jun 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Apr 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Boston, United States , Buffalo, United States , Cleveland, United States , Dallas, United States , Denver, United States , Durham, United States and 19 more locations